PharmaCytics Revenue and Competitors

OUR NUTRIENT DRUG CONJUGATE TECHNOLOGY (NDCt)™ - turns parenteral compounds into oral variants or improves oral bioavailability. - uses specific transporter proteins for food, i.e. active transport over the gut wall. - delivers tailor made solutions with our toolbox of linkers and nutrient. PATIENTS BENEFITS: - Oral administration is by far the preferred route and GI side effects may diminish, both improving compliance and with that efficacy - Enhanced bioavailability gives less inter-patient variability - New indications for the same compound BENEFITS TO COMPANIES: - Life cycle management from an NCE (new IP, often COM). - Short route to approval. - NDCt platform broadly applicable, irrespective of disease area. - Accelerate development of pipeline products. - Once promising, but now shelved research, can be revived. NDCt GIVES CONTROL OVER THE COMPOUND We chemically attach a nutrient mimic via a linker to the drug. The linker has profound effects on transport and synthesis. The nutrient mimic is a transporter substrate – recognized by the intestinal wall – facilitating active transport (vs passive transport of old-fashioned drugs). Subsequent enzymatic cleavage in the bloodstream, liberating the drug. With our patented NDCt we address the full spectrum of issues around oral bioavailability and control the compound. PROVIDING THE MISSING LINK PharmaCytics developed a toolbox of proprietary linkers and nutrient mimics. With our bifunctional linker variants it is even possible to couple drugs to biomolecules, such as proteins and antibodies. In addition, our linker technology can produce mutual prodrugs (or codrugs) in which two different synergistic acting pharmacological agents are linked together. LET US REVIVE HIDDEN TREASURES IN YOUR PIPELINE PharmaCytics brings in its expertise on medicinal chemistry, prodrug technology and drug delivery to solve and improve on your drug development issues. CALL US AND CHALLENGE US!